Bergenbio Closes Recruitment Into Trial Assessing Bemcentinib In Covid-19 Patients finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Novadiscovery raises Series A2 financing from Sanofi to advance JINKO, its best-in-class .
NovadiscoveryFebruary 16, 2021 GMT
NOVA to develop COVID-19 disease model to support Sanofi’s vaccine and therapeutic efforts
Lyon, France – 16 February 2021: Novadiscovery (“NOVA”), a leading health tech company offering JINKO, a best-in-class clinical trial simulation platform to predict drug efficacy and optimize clinical trial development, today announces that it has raised €2.5 million in a Series A2 financing round from Sanofi.
The funds will be used to advance NOVA’s
in silico clinical trial simulation platform, JINKO; to facilitate the Company’s expansion into the US; and develop a COVID-19 disease model in collaboration with Sanofi. JINKO’s workflows are designed to closely resemble those of real life clinical studies and it offers an integrated suite of applications
BerGenBio To Present Preclinical Covid-19 Data At The Conference On Retroviruses And Opportunistic Infections (CROI 2021) finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Novadiscovery raises Series A2 financing from Sanofi to advance JINKO, its best-in-class clinical trial simulation platform
NOVA to develop COVID-19 disease model to support Sanofi s vaccine and therapeutic efforts
Lyon, France - 16 February 2021: Novadiscovery ( NOVA ), a leading health tech company offering JINKO, a best-in-class clinical trial simulation platform to predict drug efficacy and optimize clinical trial development, today announces that it has raised €2.5 million in a Series A2 financing round from Sanofi.
The funds will be used to advance NOVA s
in silico clinical trial simulation platform, JINKO; to facilitate the Company s expansion into the US; and develop a COVID-19 disease model in collaboration with Sanofi. JINKO s workflows are designed to closely resemble those of real life clinical studies and it offers an integrated suite of applications from Discovery to Market Access.
Ovoca Bio is a European-based biopharmaceutical company with a focus on women s health. The Company is currently developing a novel treatment for women with hypoactive sexual desire disorder (HSDD). The Company s lead product, BP-101, a novel synthetic peptide administered through a nasal spray, is clinically validated, with Phase II and Phase III studies conducted in Russia demonstrating statistically significant improvement in a number of key efficacy outcomes, including an increase in female sexual desire and reduction of symptoms of distress associated with HSDD. Ovoca Bio is seeking to develop the drug for major global markets - in particular the United States and Europe, as well as obtain marketing approval in the Russian Federation.